Cargando…

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers

The safety and maximum tolerated dose (MTD) of erlotinib with docetaxel/carboplatin were assessed in patients with ovarian cancer. Chemonaive patients received intravenous docetaxel (75 mg m(−2)) and carboplatin (area under the curve 5) on day 1 of a 3-week cycle, and oral erlotinib at 50 (cohort 1)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vasey, P A, Gore, M, Wilson, R, Rustin, G, Gabra, H, Guastalla, J-P, Lauraine, E P, Paul, J, Carty, K, Kaye, S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410113/ https://www.ncbi.nlm.nih.gov/pubmed/18506181 http://dx.doi.org/10.1038/sj.bjc.6604371

Ejemplares similares

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer
por: O'Neill, V J, et al.
Publicado: (2002)

Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
por: Fu, Siqing, et al.
Publicado: (2022)

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
por: Liao, John B, et al.
Publicado: (2021)

Discussing maintenance therapy for ovarian, peritoneal, and fallopian tube cancers
por: Mercier, Ann Marie, et al.
Publicado: (2023)

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
por: Pecorelli, S., et al.
Publicado: (2010)

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer
por: Clamp, A R, et al.
Publicado: (2006)

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
por: Lee, Elizabeth K., et al.
Publicado: (2019)

Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations
por: Garcia, Andrew, et al.
Publicado: (2019)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
por: Wang, Yun, et al.
Publicado: (2014)

Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2020)

Peritoneal Dialysis Catheter−Fallopian Tube Fistula
por: Mandalapu, Rajendra, et al.
Publicado: (2020)

Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review
por: Zagouri, Flora, et al.
Publicado: (2015)

Tumorigenesis and peritoneal colonization from fallopian tube epithelium
por: Eddie, Sharon L., et al.
Publicado: (2015)

Aggressive surgery could overcome the extent of initial peritoneal dissemination for advanced ovarian, fallopian tube, and peritoneal carcinoma
por: Nishikimi, Kyoko, et al.
Publicado: (2020)

The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience
por: Lee, Young-Jae, et al.
Publicado: (2017)

Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
por: Martin, Jovana Y., et al.
Publicado: (2016)

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
por: Glasspool, R M, et al.
Publicado: (2014)

Safety and Efficacy of Video Laparoscopic Surgical Debulking of Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
por: Nezhat, Farr R., et al.
Publicado: (2012)

Paraganglioma of the Fallopian Tube Presenting as Isolated Fallopian Tube Torsion
por: Takeda, Akihiro, et al.
Publicado: (2022)

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
por: Molife, L Rhoda, et al.
Publicado: (2014)

Primary Papillary Adenocarcinoma of the Fallopian Tube with Ovarian Metastasis
por: Marwah, Nisha, et al.
Publicado: (2012)

Skin metastases in epithelial ovarian and fallopian tube carcinoma
por: Otsuka, Isao, et al.
Publicado: (2017)

Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
por: Lee, Maria, et al.
Publicado: (2019)

Reclassification of BRCA1 and BRCA2 variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers
por: Ha, Hyeong In, et al.
Publicado: (2020)

Pretreatment Nutritional Status in Combination with Inflammation Affects Chemotherapy Interruption in Women with Ovarian, Fallopian Tube, and Peritoneal Cancer
por: Nomoto, Naoko, et al.
Publicado: (2022)

Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary
por: Vaysse, Charlotte, et al.
Publicado: (2011)

Epithelialization of mouse ovarian tumor cells originating in the fallopian tube stroma
por: Hua, Yuanyuan, et al.
Publicado: (2016)

Probability of Fallopian Tube and Ovarian Detection with Transvaginal Ultrasonography in Normal Women
por: Lefringhouse, Jason R, et al.
Publicado: (2016)

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
por: van der Noll, Ruud, et al.
Publicado: (2015)

Duplication of the fallopian tube
por: R, Narayanan, et al.
Publicado: (2008)

Diseases of the Fallopian Tubes
Publicado: (1885)

Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention
por: George, Sophia H. L., et al.
Publicado: (2016)

High grade serous ovarian carcinomas originate in the fallopian tube
por: Labidi-Galy, S. Intidhar, et al.
Publicado: (2017)

A Contribution to the Study of Hernias of the Ovary, of the Fallopian Tube and of the Ovary and Fallopian Tube
por: Heineck, Aime Paul
Publicado: (1916)

The Safety and Efficacy of Laparoscopic Surgical Staging and Debulking of Apparent Advanced Stage Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
por: Nezhat, Farr R., et al.
Publicado: (2010)

Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study
por: Lertkhachonsuk, Arb-Aroon, et al.
Publicado: (2020)

The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer
por: Tokunaga, Hideki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ktvla9aqott5sttjpv7mlm2h6r